Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy

Chao Lin,Hao Liu,Heng Zhang,Hongyong He,He Li,Zhenbin Shen,Jin Qin,Xinyu Qin,Jiejie Xu,Yihong Sun
DOI: https://doi.org/10.18632/oncotarget.10297
2016-01-01
Oncotarget
Abstract:Background: Interleukin-13 receptor alpha 2 (IL-13R alpha 2) plays a vital role in the invasion and metastasis of various types of cancer, but its role in prognosis of patients with gastric cancer remains unknown. The aim of this study was to investigate the impact of IL-13R alpha 2 expression on the prognostic value in gastric cancer patients after surgery. Results: Increased expression of IL-13R alpha 2 in tumoral tissue was associated with decreased overall survival rate (P < 0.001). IL-13R alpha 2 expression was an independent prognostic indicator for gastric cancer (P < 0.001). Stratification analyses showed IL-13R alpha 2 expression could give some additional prognostic information in tumors of different stages, especially in advanced tumors. Integrating IL-13R alpha 2 expression with generated a better nomogram that was validated by the validation set to predict the 5-year overall survival. Methods: IL-13R alpha 2 expression was evaluated by tissue microarrays from 507 gastric cancer patients from two academic medical centers and statistically assessed for correlations with the clinical profiles and the prognosis of the patients with gastric cancer. The prognostic nomogram was designed to predict 5-year overall survival probability. Conclusions: IL-13R alpha 2 expression might be an independent prognostic factor for gastric cancer after surgical resection and could potentially be a high-priority therapeutic target. Incorporating IL-13R alpha 2 expression into the TNM staging system can provide a good prognostic model.
What problem does this paper attempt to address?